BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Cambridge Network event: Biologics in Cambridge - from Cambridge A
 ntibody Technology to MedImmune and Astra-Zeneca - Jon Green\, Dr Paul Var
 ley and Harriet Fear
DTSTART:20140121T180000Z
DTEND:20140121T203000Z
UID:TALK49150@talks.cam.ac.uk
CONTACT:Louise Rushworth
DESCRIPTION:We're delighted to welcome Jon Green\, VP Business Operations\
 , and Dr Paul Varley\, VP Science and Collaborations\, Biopharmaceutical D
 evelopment\, from MedImmune as our speakers for January's event. Jon and P
 aul will be joined by Harriet Fear\, CEO of One Nucleus.  \n\nMedImmune ha
 s built on the local legacy of Cambridge Antibody Technology\, leaders in 
 antibody technology who discovered  three marketed medicines: Humira® (ad
 alimumab)\, an important anti-TNF antibody now marketed by Abbott Laborato
 ries.1 \, Benlysta® (belimumab)\, a first new treatment for active system
 ic lupus erythematosus in decades\, now marketed by Human Genome Sciences 
 and GlaxoSmithKline2 and ABthrax® (raxibacumab) anti-anthrax antibody mar
 keted by Human Genome Sciences and GlaxoSmithKline.\n\nCommitted to Cambri
 dge\, and firmly established in local business networks and community acti
 vities\, MedImmune is proud of its strong and enduring collaborative links
  with academics\, researchers\, charities\, foundations and neighbouring c
 ompanies. By 2016\, MedImmune will be joined in Cambridge by AstraZeneca
 ’s new UK-based global research and development centre and corporate hea
 dquarters will be located at the Cambridge Biomedical Campus\, bringing to
 gether AstraZeneca’s small molecule and MedImmune’s biologics research
  and development. The decision to locate AstraZeneca’s global R&D centre
  and corporate headquarters in Cambridge underscores the UK’s internatio
 nal importance as a location for biopharmaceutical research and developmen
 t. Jon Green and Paul Varley will be talking about the past\, present and 
 future of MedImmune - Astra-Zeneca and its work here in Cambridge.   \n
 \nJoining the MedImmune speakers will be Harriet Fear\, CEO of One Nucleus
 \, an international membership organisation for life science and healthcar
 e companies\, based in Cambridge and London. A not-for-profit company\, it
  is the largest of its kind in Europe by some way with over 470 members in
 cluding pharmaceutical\, biotech\, medical device and diagnostic companies
  and associated technical and commercial service providers.\n\n\n\nT
 o book please click on this link - http://www.cambridgenetwork.co.uk/event
 s/cambridge-network-jon-green-medimmune/\n\nTimings: The talk will last fo
 r about 30-40 minutes\, followed by Q&A . There will be a light refreshmen
 ts and an opportunity to network after the event\, which we estimate will 
 end around 8.30pm.
LOCATION:MedImmune\, Sir Aaron Klug Building\, Granta Park\, Cambridge\, C
 B21 6GH
END:VEVENT
END:VCALENDAR